State of New Jersey Common Pension Fund D Sells 35,973 Shares of Xenon Pharmaceuticals Inc. $XENE

Posted by Stanley Muller on May 12th, 2026

State of New Jersey Common Pension Fund D cut its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 64.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,738 shares of the biopharmaceutical company’s stock after selling 35,973 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Xenon Pharmaceuticals were worth $885,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Xenon Pharmaceuticals by 66.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after buying an additional 1,435,096 shares in the last quarter. Commodore Capital LP lifted its holdings in shares of Xenon Pharmaceuticals by 30.1% in the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after buying an additional 700,000 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Xenon Pharmaceuticals by 53.8% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after acquiring an additional 700,000 shares during the last quarter. Holocene Advisors LP boosted its position in shares of Xenon Pharmaceuticals by 9.2% during the third quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock worth $79,359,000 after acquiring an additional 167,078 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in Xenon Pharmaceuticals by 8.9% during the third quarter. Alliancebernstein L.P. now owns 1,654,417 shares of the biopharmaceutical company’s stock valued at $66,425,000 after acquiring an additional 135,890 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Stock Down 1.2%

XENE stock opened at $55.78 on Tuesday. Xenon Pharmaceuticals Inc. has a 52 week low of $28.19 and a 52 week high of $63.95. The firm has a market capitalization of $5.39 billion, a P/E ratio of -11.87 and a beta of 0.65. The company has a fifty day simple moving average of $55.09 and a two-hundred day simple moving average of $46.80.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same quarter in the previous year, the firm earned ($0.83) EPS. As a group, analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.83 EPS for the current year.

Insider Activity

In related news, insider Andrea Difabio sold 1,342 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $74,118.66. Following the sale, the insider owned 7,301 shares in the company, valued at approximately $403,234.23. This represents a 15.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Christopher John Kenney sold 1,410 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $77,874.30. Following the completion of the sale, the insider directly owned 7,069 shares in the company, valued at approximately $390,420.87. This represents a 16.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 296,707 shares of company stock valued at $17,845,365 in the last ninety days. Insiders own 4.07% of the company’s stock.

Analyst Upgrades and Downgrades

XENE has been the topic of several research analyst reports. Guggenheim reiterated a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Wolfe Research started coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Wednesday, April 8th. Royal Bank Of Canada increased their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Wedbush cut their price target on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $74.56.

Check Out Our Latest Stock Report on Xenon Pharmaceuticals

About Xenon Pharmaceuticals

(Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.